Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alex Friedlaender

Showing results (1-10 of 106) with videos related to

Pageof 11
Sort By:
Immunotherapy|December 19, 2023
Unraveling the nexus: oncogenic drivers and immunotherapy efficacy in cancer treatmentHiba Mechahougui, Alex Friedlaender
Revue Medicale Suisse|May 29, 2020
[A new hope in the treatment of hepatocellular carcinoma]Laure Thouvenin, Alex Friedlaender
Translational Lung Cancer Research|December 13, 2023
Bringing immune-checkpoint inhibitors earlier in the management of non-small cell lung cancerMaxime Borgeaud, Alex Friedlaender, Alfredo Addeo
International Journal of Molecular Sciences|February 13, 2026
Rare, Yet Targetable: New Perspectives on Ampullary CarcinomasJames Gutmans, Alex Friedlaender, Hiba Mechahougui
Clinical Medicine Insights. Oncology|February 23, 2023
Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung CancerNathalie Baudoux, Alex Friedlaender, Alfredo Addeo
Journal for Immunotherapy of Cancer|May 22, 2020
COVID-19 and lung cancer: risks, mechanisms and treatment interactionsAlfredo Addeo, Michel Obeid, Alex Friedlaender
Frontiers in Oncology|June 24, 2020
Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 PandemicAlex Friedlaender, Chul Kim, Alfredo Addeo
Revue Medicale Suisse|May 29, 2020
[Metastatic hormone-sensitive prostate cancer: more than just androgen-deprivation therapy]Hiba Mechahougui, Vérane Achard, Alex Friedlaender
Current Oncology (Toronto, Ont.)|May 26, 2023
Precision Oncology in Gastrointestinal Stromal TumorsHiba Mechahougui, Montemurro Michael, Alex Friedlaender
Current Oncology Reports|November 4, 2021
The Role and Impact of Minimal Residual Disease in NSCLCDaniele Frisone, Alex Friedlaender, Alfredo Addeo
Pageof 11

Showing results (1-10 of 106) with videos related to

Sort By:
Pageof 11
Immunotherapy|December 19, 2023
Unraveling the nexus: oncogenic drivers and immunotherapy efficacy in cancer treatmentHiba Mechahougui, Alex Friedlaender
Revue Medicale Suisse|May 29, 2020
[A new hope in the treatment of hepatocellular carcinoma]Laure Thouvenin, Alex Friedlaender
Translational Lung Cancer Research|December 13, 2023
Bringing immune-checkpoint inhibitors earlier in the management of non-small cell lung cancerMaxime Borgeaud, Alex Friedlaender, Alfredo Addeo
International Journal of Molecular Sciences|February 13, 2026
Rare, Yet Targetable: New Perspectives on Ampullary CarcinomasJames Gutmans, Alex Friedlaender, Hiba Mechahougui
Clinical Medicine Insights. Oncology|February 23, 2023
Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung CancerNathalie Baudoux, Alex Friedlaender, Alfredo Addeo
Journal for Immunotherapy of Cancer|May 22, 2020
COVID-19 and lung cancer: risks, mechanisms and treatment interactionsAlfredo Addeo, Michel Obeid, Alex Friedlaender
Frontiers in Oncology|June 24, 2020
Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 PandemicAlex Friedlaender, Chul Kim, Alfredo Addeo
Revue Medicale Suisse|May 29, 2020
[Metastatic hormone-sensitive prostate cancer: more than just androgen-deprivation therapy]Hiba Mechahougui, Vérane Achard, Alex Friedlaender
Current Oncology (Toronto, Ont.)|May 26, 2023
Precision Oncology in Gastrointestinal Stromal TumorsHiba Mechahougui, Montemurro Michael, Alex Friedlaender
Current Oncology Reports|November 4, 2021
The Role and Impact of Minimal Residual Disease in NSCLCDaniele Frisone, Alex Friedlaender, Alfredo Addeo
Pageof 11